Annamaria Biczok1,2, Christine Jungk3,4, Rupert Egensperger5,3, Andreas von Deimling3,6, Bogdana Suchorska7,3, Joerg C Tonn7,3, Christel Herold-Mende3,4, Christian Schichor7,3. 1. Department of Neurosurgery, Ludwig-Maximilians-University Munich, Marchioninistr. 15, 81377, Munich, Germany. annamaria.biczok@med.uni-muenchen.de. 2. German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Partner Site Munich, Heidelberg, Germany. annamaria.biczok@med.uni-muenchen.de. 3. German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Partner Site Munich, Heidelberg, Germany. 4. Department of Neurosurgery, University Hospital, Heidelberg, Germany. 5. Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Munich, Germany. 6. Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany. 7. Department of Neurosurgery, Ludwig-Maximilians-University Munich, Marchioninistr. 15, 81377, Munich, Germany.
Abstract
PURPOSE: For meningiomas, the 2016 revision of the WHO classification introduced brain invasion per se as a sufficient condition to classify as grade II. We analyzed whether meningiomas previously graded as WHO grade I differ in prognosis depending on the presence of microscopic brain invasion. METHODS: A consecutive series of patients with intracranial meningioma WHO grade I (± brain invasion) at two neurosurgical departments was analyzed retrospectively. Cox regression models on progression-free survival (PFS) and Kaplan-Meier survival estimates were performed. RESULTS: 875 adult patients were included. Histological diagnosis of brain invasion was confirmed in 28 patients. Median follow-up was 73 months. In univariate and multivariate models, gross total resection gained favorable prognostic influence for PFS (p < 0.001, HR: 0.237, CI 0.170-0.382). 170 patients with the brain/meningioma interface present in histopathological specimen were separately analyzed as a subgroup. Importantly, presence of brain invasion did not reach significance for PFS, even in the subgroup with available specimen of brain/meningioma interface (p = 0.787, HR: 0.852, CI 0.268-2.710 and p = 0.811, HR: 0.848, CI 0.222-3.246, respectively). Patients with and without brain invasion did not differ in terms of age, tumor location and extent of resection, but were more likely to receive radiotherapy (p = 0.03) of tumor remnants. However, subgroup analysis of non-irradiated tumors revealed no prognostic influence of brain invasion (p = 0.749, HR: 0.772, CI 0.158-3.767). CONCLUSIONS: In this bi-institutional series, brain invasion was frequent among meningiomas WHO grade I when brain/meningioma interface was available for histology (16.5%). However, brain invasion did not impact early recurrence.
PURPOSE: For meningiomas, the 2016 revision of the WHO classification introduced brain invasion per se as a sufficient condition to classify as grade II. We analyzed whether meningiomas previously graded as WHO grade I differ in prognosis depending on the presence of microscopic brain invasion. METHODS: A consecutive series of patients with intracranial meningioma WHO grade I (± brain invasion) at two neurosurgical departments was analyzed retrospectively. Cox regression models on progression-free survival (PFS) and Kaplan-Meier survival estimates were performed. RESULTS: 875 adult patients were included. Histological diagnosis of brain invasion was confirmed in 28 patients. Median follow-up was 73 months. In univariate and multivariate models, gross total resection gained favorable prognostic influence for PFS (p < 0.001, HR: 0.237, CI 0.170-0.382). 170 patients with the brain/meningioma interface present in histopathological specimen were separately analyzed as a subgroup. Importantly, presence of brain invasion did not reach significance for PFS, even in the subgroup with available specimen of brain/meningioma interface (p = 0.787, HR: 0.852, CI 0.268-2.710 and p = 0.811, HR: 0.848, CI 0.222-3.246, respectively). Patients with and without brain invasion did not differ in terms of age, tumor location and extent of resection, but were more likely to receive radiotherapy (p = 0.03) of tumor remnants. However, subgroup analysis of non-irradiated tumors revealed no prognostic influence of brain invasion (p = 0.749, HR: 0.772, CI 0.158-3.767). CONCLUSIONS: In this bi-institutional series, brain invasion was frequent among meningiomas WHO grade I when brain/meningioma interface was available for histology (16.5%). However, brain invasion did not impact early recurrence.
Entities:
Keywords:
Meningioma; Microscopic brain invasion; Prognostic factor; WHO grade I
Authors: Leland Rogers; Igor Barani; Marc Chamberlain; Thomas J Kaley; Michael McDermott; Jeffrey Raizer; David Schiff; Damien C Weber; Patrick Y Wen; Michael A Vogelbaum Journal: J Neurosurg Date: 2015-01 Impact factor: 5.115
Authors: Maximilian Timme; Christian Thomas; Dorothee Cäcilia Spille; Walter Stummer; Heinrich Ebel; Christian Ewelt; Franz-Josef Hans; Uta Schick; Maximilian Puchner; Uwe Wildförster; Bernhard Bruns; Hans Axel Trost; Markus Holling; Oliver Grauer; Katharina Hess; Benjamin Brokinkel Journal: Neurosurg Rev Date: 2019-06-03 Impact factor: 3.042
Authors: Sam Q Sun; Albert H Kim; Chunyu Cai; Rory K J Murphy; Todd DeWees; Peter Sylvester; Ralph G Dacey; Robert L Grubb; Keith M Rich; Gregory J Zipfel; Joshua L Dowling; Eric C Leuthardt; Jeffrey R Leonard; John Evans; Joseph R Simpson; Clifford G Robinson; Richard J Perrin; Jiayi Huang; Michael R Chicoine Journal: Neurosurgery Date: 2014-10 Impact factor: 4.654
Authors: Heinz Georg Bloss; Martin A Proescholdt; Christina Mayer; Andreas G Schreyer; Alexander Brawanski Journal: Acta Neurochir (Wien) Date: 2010-01 Impact factor: 2.216
Authors: Felix Sahm; Daniel Schrimpf; Adriana Olar; Christian Koelsche; David Reuss; Juliane Bissel; Annekathrin Kratz; David Capper; Sebastian Schefzyk; Thomas Hielscher; Qianghu Wang; Erik P Sulman; Sebastian Adeberg; Arend Koch; Ali Fuat Okuducu; Stefanie Brehmer; Jens Schittenhelm; Albert Becker; Benjamin Brokinkel; Melissa Schmidt; Theresa Ull; Konstantinos Gousias; Almuth Friederike Kessler; Katrin Lamszus; Jürgen Debus; Christian Mawrin; Yoo-Jin Kim; Matthias Simon; Ralf Ketter; Werner Paulus; Kenneth D Aldape; Christel Herold-Mende; Andreas von Deimling Journal: J Natl Cancer Inst Date: 2015-12-13 Impact factor: 13.506
Authors: Haley R Gittleman; Quinn T Ostrom; Chaturia D Rouse; Jacqueline A Dowling; Peter M de Blank; Carol A Kruchko; J Bradley Elder; Steven S Rosenfeld; Warren R Selman; Andrew E Sloan; Jill S Barnholtz-Sloan Journal: Cancer Date: 2014-08-25 Impact factor: 6.860
Authors: Roland Goldbrunner; Giuseppe Minniti; Matthias Preusser; Michael D Jenkinson; Kita Sallabanda; Emmanuel Houdart; Andreas von Deimling; Pantelis Stavrinou; Florence Lefranc; Morten Lund-Johansen; Elizabeth Cohen-Jonathan Moyal; Dieta Brandsma; Roger Henriksson; Riccardo Soffietti; Michael Weller Journal: Lancet Oncol Date: 2016-08-30 Impact factor: 41.316
Authors: Niklas von Spreckelsen; Christoph Kesseler; Benjamin Brokinkel; Roland Goldbrunner; Arie Perry; Christian Mawrin Journal: Brain Pathol Date: 2022-03 Impact factor: 6.508